Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

Helen M. Colhoun (Lead / Corresponding author), Jennifer G. Robinson, Michel Farnier, Bertrand Cariou, Dirk Blom, Dean J. Kereiakes, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari

    Research output: Contribution to journalArticlepeer-review

    41 Citations (Scopus)

    Abstract

    Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.
    Original languageEnglish
    Pages (from-to)121
    JournalBMC Cardiovascular Disorders
    Volume14
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials'. Together they form a unique fingerprint.

    Cite this